GANX
Gain Therapeutics, Inc.
Biotechnology
Market Cap$67M
5Y Perf.-87.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
GANX vs RARE
Revenue, margins, valuation, and 5-year total return — side by side.
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.57B
5Y Perf.-77.1%
GANX vs RARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | GANX | RARE |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $67M | $2.57B |
| Revenue (TTM) | $0.00 | $669M |
| Net Income (TTM) | $-19M | $-609M |
| Gross Margin | — | 83.6% |
| Operating Margin | — | -83.9% |
| Total Debt | $653K | $1.28B |
| Cash & Equiv. | $10M | $434M |
GANX vs RARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
GANX
RARE
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| Gain Therapeutics, … (GANX) | 100 | 12.5 | -87.5% |
| Ultragenyx Pharmace… (RARE) | 100 | 22.9 | -77.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GANX vs RARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RARE leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Gain Therapeutics, Inc. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
GANX
Gain Therapeutics, Inc.
The Quality Compounder
GANX is the clearest fit if your priority is quality and momentum.
- 2.9% margin vs RARE's -91.0%
- -4.1% vs RARE's -21.8%
Best for: quality and momentum
RARE
Ultragenyx Pharmaceutical Inc.
The Income Pick
RARE carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 1.42
- Rev growth 20.1%, EPS growth 7.3%, 3Y rev CAGR 22.8%
- -59.4% 10Y total return vs GANX's -83.3%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RARE | 20.1% revenue growth vs GANX's -100.0% |
| Quality / Margins | GANX | 2.9% margin vs RARE's -91.0% |
| Stability / Safety | RARE | Beta 1.42 vs GANX's 1.46 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | GANX | -4.1% vs RARE's -21.8% |
| Efficiency (ROA) | RARE | -45.8% ROA vs GANX's -176.7% |
GANX vs RARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
GANX vs RARE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRARELAGGINGGANX
GANXGain Therapeutics, In…
1leads
RAREUltragenyx Pharmaceut…
3leads
6 Total Categories
CATEGORYLEADERvs GANXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
GANX1/1
Valuation MetricsMultiples, price ratios, and targets
RARE1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
RARE5/6
Risk & VolatilityBeta, volatility, and downside exposure
RARE2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
GANX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
RARE and GANX operate at a comparable scale, with $669M and $0 in trailing revenue.
| Metric | GANXGain Therapeutics… | RAREUltragenyx Pharma… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $669M |
| EBITDAEarnings before interest/tax | -$18M | -$536M |
| Net IncomeAfter-tax profit | -$19M | -$609M |
| Free Cash FlowCash after capex | -$17M | -$487M |
| Gross MarginGross profit ÷ Revenue | — | +83.6% |
| Operating MarginEBIT ÷ Revenue | — | -83.9% |
| Net MarginNet income ÷ Revenue | — | -91.0% |
| FCF MarginFCF ÷ Revenue | — | -72.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +11.2% | -17.2% |
GANX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
RARE leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | GANXGain Therapeutics… | RAREUltragenyx Pharma… |
|---|---|---|
| Market CapShares × price | $67M | $2.6B |
| Enterprise ValueMkt cap + debt − cash | $58M | $3.4B |
| Trailing P/EPrice ÷ TTM EPS | -2.10x | -4.48x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 3.82x |
| Price / BookPrice ÷ Book value/share | 5.83x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
RARE leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
Evenly matched — GANX and RARE each lead in 3 of 6 comparable metrics.
Profitability & Efficiency
GANX delivers a -3.3% return on equity — every $100 of shareholder capital generates $-3 in annual profit, vs $-6 for RARE. On the Piotroski fundamental quality scale (0–9), RARE scores 4/9 vs GANX's 2/9, reflecting mixed financial health.
| Metric | GANXGain Therapeutics… | RAREUltragenyx Pharma… |
|---|---|---|
| ROE (TTM)Return on equity | -3.3% | -6.1% |
| ROA (TTM)Return on assets | -176.7% | -45.8% |
| ROICReturn on invested capital | — | -89.4% |
| ROCEReturn on capital employed | -186.1% | -46.4% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.09x | — |
| Net DebtTotal debt minus cash | -$10M | $842M |
| Cash & Equiv.Liquid assets | $10M | $434M |
| Total DebtShort + long-term debt | $653,015 | $1.3B |
| Interest CoverageEBIT ÷ Interest expense | — | -14.49x |
Evenly matched — GANX and RARE each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
RARE leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RARE five years ago would be worth $2,281 today (with dividends reinvested), compared to $1,781 for GANX. Over the past 12 months, GANX leads with a -4.1% total return vs RARE's -21.8%. The 3-year compound annual growth rate (CAGR) favors RARE at -17.8% vs GANX's -29.4% — a key indicator of consistent wealth creation.
| Metric | GANXGain Therapeutics… | RAREUltragenyx Pharma… |
|---|---|---|
| YTD ReturnYear-to-date | -41.2% | +10.7% |
| 1-Year ReturnPast 12 months | -4.1% | -21.8% |
| 3-Year ReturnCumulative with dividends | -64.8% | -44.5% |
| 5-Year ReturnCumulative with dividends | -82.2% | -77.2% |
| 10-Year ReturnCumulative with dividends | -83.3% | -59.4% |
| CAGR (3Y)Annualised 3-year return | -29.4% | -17.8% |
RARE leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
RARE leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
RARE is the less volatile stock with a 1.42 beta — it tends to amplify market swings less than GANX's 1.46 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RARE currently trades 61.7% from its 52-week high vs GANX's 43.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | GANXGain Therapeutics… | RAREUltragenyx Pharma… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.46x | 1.42x |
| 52-Week HighHighest price in past year | $4.34 | $42.37 |
| 52-Week LowLowest price in past year | $1.41 | $18.29 |
| % of 52W HighCurrent price vs 52-week peak | +43.1% | +61.7% |
| RSI (14)Momentum oscillator 0–100 | 47.2 | 66.6 |
| Avg Volume (50D)Average daily shares traded | 640K | 1.8M |
RARE leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates GANX as "Buy" and RARE as "Buy". Consensus price targets imply 345.5% upside for GANX (target: $8) vs 97.1% for RARE (target: $52).
| Metric | GANXGain Therapeutics… | RAREUltragenyx Pharma… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $8.33 | $51.50 |
| # AnalystsCovering analysts | 8 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RARE leads in 3 of 6 categories (Valuation Metrics, Total Returns). GANX leads in 1 (Income & Cash Flow). 1 tied.
Best OverallUltragenyx Pharmaceutical I… (RARE)Leads 3 of 6 categories
Loading custom metrics...
GANX vs RARE: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is GANX or RARE a better buy right now?
For growth investors, Ultragenyx Pharmaceutical Inc.
(RARE) is the stronger pick with 20. 1% revenue growth year-over-year, versus -100. 0% for Gain Therapeutics, Inc. (GANX). Analysts rate Gain Therapeutics, Inc. (GANX) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — GANX or RARE?
Over the past 5 years, Ultragenyx Pharmaceutical Inc.
(RARE) delivered a total return of -77. 2%, compared to -82. 2% for Gain Therapeutics, Inc. (GANX). Over 10 years, the gap is even starker: RARE returned -59. 4% versus GANX's -83. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — GANX or RARE?
By beta (market sensitivity over 5 years), Ultragenyx Pharmaceutical Inc.
(RARE) is the lower-risk stock at 1. 42β versus Gain Therapeutics, Inc. 's 1. 46β — meaning GANX is approximately 3% more volatile than RARE relative to the S&P 500.
04Which is growing faster — GANX or RARE?
By revenue growth (latest reported year), Ultragenyx Pharmaceutical Inc.
(RARE) is pulling ahead at 20. 1% versus -100. 0% for Gain Therapeutics, Inc. (GANX). On earnings-per-share growth, the picture is similar: Gain Therapeutics, Inc. grew EPS 48. 0% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — GANX or RARE?
Gain Therapeutics, Inc.
(GANX) is the more profitable company, earning 0. 0% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GANX leads at 0. 0% versus -79. 5% for RARE. At the gross margin level — before operating expenses — RARE leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — GANX or RARE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is GANX or RARE better for a retirement portfolio?
For long-horizon retirement investors, Ultragenyx Pharmaceutical Inc.
(RARE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Both have compounded well over 10 years (RARE: -59. 4%, GANX: -83. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between GANX and RARE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: GANX is a small-cap quality compounder stock; RARE is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(GANX: -100.0% · RARE: -2.4%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.